Educational Symposium

Recognizing and Managing Atypical Hemolytic Uremic Syndrome in Complex Clinical Settings

November 07, 2019 | 12:45 PM - 01:45 PM

Location: TBD 2, Marriott Marquis

Session Description

Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening disease with strong genetic underpinnings. It is characterized by uncontrolled complement activation leading to thrombotic microangiopathy (TMA) and subsequent kidney and vital organ damage. As a diagnosis of exclusion, aHUS must be differentiated from the two other forms of TMA that have similar clinical presentations – thrombotic thrombocytopenic purpura (TTP) and Shiga toxin-producing Escherichia coli hemolytic uremic syndrome (STEC-HUS). This symposium reviews the pathogenesis and diagnostic criteria for aHUS, particularly in the setting of triggers that can independently increase complement activity. Recent advances in the treatment of aHUS are also discussed.

Support is provided by an educational grant from Alexion Pharmaceuticals, Inc.

Learning Objective(s)

  • Identify the clinical features required to diagnose aHUS in complement-amplifying conditions
  • Describe the mechanistic rationale and approach for current therapeutic interventions in aHUS

Learning Pathway(s)

  • Genetic Diseases of the Kidneys


  • Sjoerd Timmermans, MD


  • Introduction
    12:45 PM - 12:55 PM
  • Pathogenesis and Diagnosis of aHUS
    12:55 PM - 01:15 PM
  • Approach to the Treatment of aHUS
    01:15 PM - 01:35 PM
    Andrew M. Siedlecki, MD, FASN
  • Questions and Answers
    01:35 PM - 01:45 PM